Triple receptor agonist targeting GLP-1R, GIPR, and glucagon receptor simultaneously. Under active investigation in metabolic signaling research. Third-party HPLC verified, ≥99.4% purity, COA available.
Retatrutide is a synthetic long-acting peptide that acts simultaneously as a triple agonist at the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GcgR). This unique triple-agonist profile has made it a subject of intense scientific investigation.
As a research compound classified for Research Use Only (RUO), Retatrutide has been the subject of numerous preclinical investigations focusing on metabolic receptor signaling, adipose tissue dynamics, hepatic glucose production, and related biochemical pathways.
⚠️ VialX supplies this compound exclusively for in vitro and laboratory research. No medical or therapeutic claims are made or implied.
The following represent documented in vitro and preclinical research contexts (not therapeutic recommendations):
All batches are independently tested by trusted community labs before sale. Results are publicly verifiable using the keys below.
All results are independently verifiable using the keys above. COA PDFs available on request via the contact page.
The following is a summary of published scientific literature on Retatrutide. All information is provided for informational and research context only. VialX makes no therapeutic claims.
Published research has investigated the pharmacodynamic profile of retatrutide, demonstrating simultaneous agonism at GLP-1R, GIPR, and glucagon receptors. Preclinical data showed significant effects on adipose tissue and hepatic function in animal models (for research context only).
Studies characterizing the binding affinity of triple incretin agonists to their respective GPCRs. Researchers have noted differential potency ratios at GLP-1R vs. GIPR vs. GcgR which may be relevant for in vitro dose-response modeling.
In vitro research examining the downstream signaling cascades activated in adipocyte cell lines exposed to triple receptor agonists. cAMP accumulation assays and downstream MAPK pathway analysis have been areas of particular interest.
RUO means the compound is intended solely for in vitro laboratory and scientific research. It is NOT approved for human consumption, therapeutic use, clinical trials without IND approval, or veterinary use. Purchasers assume full legal responsibility.
Retatrutide is a synthetic research peptide that is not currently a scheduled controlled substance in the US. However, laws vary by jurisdiction and change over time. You are solely responsible for understanding and complying with all applicable laws in your area.
All orders ship from our US-based fulfillment warehouse within 48 hours of payment confirmation. Products are shipped in plain, discreet packaging with cold packs for peptides. Domestic shipping typically takes 2–5 business days.
Yes. A Certificate of Analysis is available for every batch we sell. The COA includes HPLC purity data, mass spectrometry identity confirmation, and batch-specific lot numbers. Contact us to request a full PDF COA.
We accept major credit/debit cards via our secure checkout, ACH bank transfer, and cryptocurrency (Bitcoin, USDC). All payments are processed through our secure checkout portal.
Due to the nature of research compounds, we do not accept returns on opened products. Damaged or incorrectly shipped items will be replaced at no cost. Contact our team within 7 days of delivery for any issues.
Your cart is empty.